arrow
M

Malini Gandhi

dana–farber cancer institute
H指数:11
被引数:374

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

TTF-1在肺腺癌中的表达:临床病理、基因组学、免疫表型相关性及对免疫治疗基础疗法和KRASG12C抑制剂的预后影响

2026-02-120
PRE
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

MET激酶域激活突变与其他驱动癌基因共发生,并介导非小细胞肺癌对靶向治疗的耐药性

2025-04-020
PRE
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

黏液性组织学特征的肺腺癌:临床、基因组学和免疫微环境特征及对基于免疫疗法治疗和KRASG12C抑制剂的疗效

2025-03-014
PRE
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients

老年非小细胞肺癌患者(≥80岁)的肿瘤免疫表型相关性及PD-L1高表达(≥50%)患者接受一线帕博利珠单抗治疗的结局

2025-02-040
PRE
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC

STK11、KEAP1和SMARCA4基因拷贝数缺失:临床病理特征及其与免疫治疗联合或单独化疗在非鳞状NSCLC中疗效的关联

2025-01-270
PRE
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer

非小细胞肺癌患者PD-L1表达和肿瘤突变负荷的体内变化及其对免疫检查点抑制剂治疗结局的影响

2024-10-010
PRE
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
2024-09-013
OA
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
2024-04-023
OAAI
Evaluation of GeneXpert and advanced biological laboratories UltraGene HCV diagnostic detection and performance against Roche real time PCR in Myanmar
2024-04-010
OAAI
Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small cell lung cancer
2023-04-040
PRE